Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

st physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGFbeta3) and veleglucerase alfa (GA-GCB); manufacturing and commercialisation including, but not limited to, the establishment in the market of YVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine ex
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 After the ... reason that the next beverage craze is going to ... today that formulators can use Stress Relief energy pattern ... in the making of a beverage, including minerals, herbs ... stress-generated energy, channeling that power into rapid recovery and ...
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Symbol: MS, EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced financial ... 30, 2008. BioMS Medical, in partnership with Eli ... drug for the,treatment of MS undergoing pivotal trials ...
... MEMY ) today announced that Michael Smith, Chief ... company update at,the Rodman & Renshaw Annual Global Investment ... at the New York Palace Hotel, in New,York City., ... the presentation by,visiting the "Investors" section of Memory Pharmaceuticals, ...
... in Albuferon(R) Phase 3 trials; first Phase 3 data in ... December 2008 -, - Enrollment completed in LymphoStat-B(R) Phase 3 trials; first Phase ... data in mid-2009 - ... updates financial guidance -, ROCKVILLE, Md., Nov. 6 Human Genome Sciences,Inc. (Nasdaq: HGSI ) ...
Cached Biology Technology:BioMS Medical Announces Third Quarter 2008 Results 2BioMS Medical Announces Third Quarter 2008 Results 3BioMS Medical Announces Third Quarter 2008 Results 4BioMS Medical Announces Third Quarter 2008 Results 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10
(Date:8/27/2014)... want to listen carefully to someone, the first thing ... do is stop moving altogether. This strategy helps us ... own movements. , This interplay between movement and hearing ... indirect evidence has long suggested that the brain,s motor ... which gives rise to our conscious perception of sound. ...
(Date:8/27/2014)... release is available in German . ... is the most common inherited disease affecting the peripheral ... the Max Planck Institute of Experimental Medicine and University ... Schwann cells is impaired in rats with the disease. ... layer known as myelin, which facilitates the rapid transfer ...
(Date:8/27/2014)... or abandoned each year in U.S. waters and become ... catch fish, crabs, and other species such as turtles. ... the watermen who depend on the resources--losses that are ... , The report, published in the Marine Pollution ... examine the derelict fish trap problem, and so-called "ghost ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Potential therapy for incurable Charcot-Marie-Tooth disease 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... robust, efficient method of using hydrogen as a fuel source. ... converted to electricity in a fuel cell and because it is ... a gas, it can only be stored in high pressure or ... of hydrogen, "if you got into a wreck, you,d have a ...
... CORVALLIS, Ore. As wolf populations grow in parts of ... value in aiding broader ecosystem recovery but a new ... could play an important role in helping to save other ... Bulletin, scientists suggest that a key factor in the Canada ...
... CAMBRIDGE, Mass. -- New research from MIT suggests that ... and only language, a finding that marks a major ... sophisticated mental functions. Functional specificity, as it,s known ... parts of the brain handle distinct tasks. Scientists have ...
Cached Biology News:Wolves may aid recovery of Canada lynx, a threatened species 2Localizing language in the brain 2Localizing language in the brain 3Localizing language in the brain 4
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Biology Products: